Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Heparin for COVID-19 ARDS
NCT04842292Phase 2Terminated
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of heparin in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS). Started May 2021; status: terminated.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04842292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842292.